Generic Name and Formulations:
Sacrosidase 8500 IU/mL; oral soln.
QOL Medical, LLC
Indications for SUCRAID:
Oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency.
<5months: not recommended. ≥5months: ≤15kg: 8500 IU per meal or snack. >15kg: 17000 IU per meal or snack. Dilute dose with 2–4 ounces of water, milk, or infant formula. Serve cold or at room temp; do not warm up or heat liquid before or after addition of Sucraid. Give half the dose at the beginning of the meal/snack and the remainder during meal/snack.
Hypersensitivity to yeast, glycerin, papain.
Administer initial dose near facility where acute hypersensitivity reactions can be treated; discontinue if hypersensitivity occurs. Diabetes. Evaluate for dietary starch restriction. Secondary disaccharidase deficiencies. Pregnancy (Cat. C).
Do not reconstitute or consume with fruit juice; acidity reduces enzyme activity.
Abdominal pain, GI upset, constipation, insomnia, headache, nervousness, dehydration; rare: wheezing.
Soln (118mL)—2 bottles (w. measuring scoops)
Endocrinology Advisor Articles
- Triple-Goal Achievement Reduces Risk for Complications in Type 2 Diabetes
- Inverse Association Between Serum 25(OH)D Levels and Risk for Diabetes
- ADA Issues White Paper Addressing Escalating Cost of Insulin
- Neprilysin Inhibition May Reduce Renal Function Deterioration in Comorbid T2D and Chronic Heart Failure
- Serum Chemerin May Predict Risk for Spontaneous Abortion in Women With PCOS
- Diabetes Treatments
- Incretins, Thiazolidinediones Associated With Better Glycemic Control in T2D
- No Link Between HbA1c Levels and Wound Healing in Patients With Diabetic Foot Ulcers
- Risk for Fetal Loss Early in Pregnancy Not Greater With Noninsulin vs Insulin Therapy
- Use of In-Hospital Continuous Subcutaneous Insulin Infusion: A Consensus Statement
- Effects of Gender on Clinical Outcomes in Empagliflozin-Treated Type 2 Diabetes
- Effect of Acetyl-L-Carnitine on Blood Pressure in Type 2 Diabetes
- PAH Risk, Mortality Increased by Disturbances in Male Sex Hormones
- Perioperative Cardiovascular Events More Common in Diabetes
- Individuals With Type 1 Diabetes See Improvement With Continuous Glucose Monitoring